Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence

Inclusion Criteria: * Males and Females 18-65 years old * VEINES Sym Score less than 75 points * Varicose Vein clinical classification CEAP 2, 3, 4, or 5 * Incompetence of SFJ associated with incompetence of the GSV or other major accessory vein * Superficial venous disease manifested by both symptoms and visible varicosities * Ability to comprehend and sign an informed consent document and completed study questionnaires in English Exclusion Criteria: * Incompetence of the SSV which substantially contributes to the filling of visible varicose veins * Current or previous Deep Vein Thrombosis * Leg obesity * Peripheral arterial disease in the leg to be treated * Reduced mobility * Planned prolonged travel with limited mobility with in 4 weeks of treatment * History of pulmonary embolism or stroke * Major surgery, prolonged hospitalization or pregnancy within 3 months * Current anticoagulation therapy (within 7 days of enrollment) * Participation in a clinical study involving a investigational product within 3 months * Major co-existing disease or clinically significant laboratory abnormalities * Known allergic response to polidocanol or heparin or severe and/or multiple allergic reactions * Women of childbearing potential not using effective contraception one month prior to enrollment and/or unwilling to continue while on study * Pregnant or lactating women * Current alcohol or drug abuse